RAD BioMed

RAD BioMed operates within the RAD Bynet Group ecosystem, which has spawned over 17 technology companies since the 1980s. Deal flow comes primarily through the group's internal network of entrepreneurs, engineers, and repeat founders, with a secondary channel emerging from the firm's partnership with Square One Labs for deep tech ventures. The firm describes itself as an accelerator, suggesting hands-on company formation rather than passive scouting.

Yes. While MedTech remains the core, the firm's website now lists Health, Technology, and Energy as target sectors. Recent portfolio additions include in-wheel suspension technology for e-mobility and a partnership with Square One Labs to build companies in energy and physical AI. This marks a deliberate expansion from RAD BioMed’s original healthcare-only mandate.

RAD BioMed functions more like an accelerator and investment arm than a traditional VC fund. It is wholly part of the RAD Bynet Group and provides in-house legal, business development, and operational support to its portfolio companies. The firm does not appear to raise external LP capital, reinforcing its structure as a strategic company builder rather than a pooled investment vehicle.

Prof. Nava Zisapel is co-founder and chairperson of RAD BioMed, a full professor of neuro-biochemistry at Tel Aviv University, and founder of CNS drug developer Neurim Pharmaceuticals. Her scientific background directly shapes the firm's diligence on medical-device and life-science deals, with a particular focus on neurological and ophthalmic applications evident in the portfolio.

The firm enters at the very earliest stages — seed and start-up — often providing the first institutional capital and operational scaffolding. RAD BioMed's model is designed to take a company from concept through to commercial launch, with exits like Vectorious (acquired by Edwards) and Belkin Vision (acquired by Alcon) illustrating a path from incubation to strategic acquisition.

The firm's website and available materials do not explicitly describe a co-investment program with external VCs. However, its recent partnership with Square One Labs suggests it is willing to collaborate with other entities, particularly where deep tech development requires complementary expertise outside the RAD Bynet Group's core IT and healthcare strengths.

RAD BioMed is a direct subsidiary and the designated healthcare investment arm. It shares back-office, legal, and strategic resources with sibling companies that have collectively achieved 9 IPOs and 10 M&A exits. This linkage allows portfolio companies to access RAD Bynet's IT, cybersecurity, and infrastructure expertise, creating a cross-pollination effect uncommon in standalone MedTech incubators.